The acquisition of an injectable manufacturing facility in the United States, integrated into the Group under the brand name ROIS PHOENIX, represents a strategic milestone in the development of the contract manufacturing business (CDMO) of Rovi Pharmaceutical Services, S.A.U. (hereinafter, “ROIS”). This transaction is a decisive step forward in the company’s development: from a strong European base –forged over decades of experience, reliability and regulatory compliance– to a global industrial company capable of meeting the manufacturing and development needs of the pharmaceutical industry across the main international markets.

The transaction responds to a long-term vision: to consolidate ROIS as a leading industrial partner for pharmaceutical and biotechnology companies in an environment in which supply chain resilience, regulatory excellence and production outsourcing have become key competitive factors.

From a strong European base to global industrial presence

ROIS has built its growth on a European industrial base recognised for its operational excellence, flexibility and ability to manage complex injectable manufacturing processes. This track record has allowed the company to position itself among the main global players in the aseptic filling of prefilled syringes, cartridges and vials, covering from compounding to pen/auto-injector assembly and final packaging.

The addition of ROIS PHOENIX reinforces this strategy by establishing a direct industrial presence in the United States, one of the world’s most important and demanding pharmaceutical markets. This geographic expansion helps diversify operating risk, strengthen supply continuity and expand the company’s ability to secure international projects.

ROIS PHOENIX as a driver of growth and value creation

Under the ROIS PHOENIX brand, the company provides specialised contract manufacturing, pharmaceutical development, quality control and technical support services for pharmaceutical and biotechnology companies, supporting customers from the development phases through to commercial production.

Likewise, ROIS provides commercial industrial capabilities that are already operating in highly specialised areas, such as filling and packaging, as well as vial lyophilisation in segregated environments for cytotoxic products. In addition, the facility has the capability to fill antibody-drug conjugates (ADCs), further strengthening its position in the high-value-added therapies market. Furthermore, it holds international regulatory approvals, facilitating its integration into the ROIS industrial network.

The transaction also encompasses additional investments intended to expand the filling and packaging capacities for biotechnology products, including the addition of a new line with an isolator to fill prefilled syringes. These initiatives will allow the Group’s overall filling production capacity to increase significantly and enhance the visibility of the CDMO business’s medium- and long-term growth, in line with the target of doubling this business’s operating revenue by 2030 compared with 2024 levels.

Response to structural demand of the CDMO market

The global contract manufacturing market is showing sustained growth driven by increasing outsourcing of services, rising R&D investment by pharmaceutical companies and limitations on in-house capacity. This trend is reinforced by the development of increasingly complex therapies, particular in the area of biologics and biosimilars and high-impact innovative treatments such as GLP-1 medications.

At the same time, injectables are consolidating their position as the fastest growing route of administration, accounting for a majority of medicines in development, driven by the global increase in chronic diseases and the need for effective, fast-acting treatments.

In this context, CDMO companies play a key role in providing highly-specialised capabilities in complex aseptic filling, assembly and packaging processes, as well as compliance with increasingly demanding regulatory standards. This increases dependence on reliable and qualified external partners.

The combination of capabilities in Europe and the United States places ROIS in a competitive position to meet the growing demand for high-value sterile injectables. For pharmaceutical companies, this transatlantic presence facilitates more efficient and secure supply strategies while, for healthcare systems and regulatory authorities, it helps reinforce continuity in the supply of essential medicines.

A decision aligned with ROIS’s strategy

The acquisition of ROIS PHOENIX reflects < consistent strategy of selective growth for ROIS’s CDMO business, strengthening its ability to compete on the international stage without losing the hallmark of reliability it has built in Europe. In a sector with

growing demand for strong industrial partners, this transaction places ROVI in a position to attract new projects, support global customers and continue contributing to the stability of supply in the markets where it operates.